News more

  • Foley Hoag Represents Inverness Medical Innovations in Transaction with Epocal, Inc.  [Read More]
  • New Leadership at Foley Hoag: William Kolb and Adam Kahn Named Co-Managing Partners, Succeeding Robert Sanoff  [Read More]
  • Foley Hoag Names New Partners for 2010, Corporate and Litigation Practices Represented  [Read More]
  • NAIOP Presents Foley Hoag Lawyers Seth Jaffe and Rebecca Puskas with Public Affairs Award  [Read More]
  • Visit Foley Hoag LLP's New Emerging Enterprise Center Web site  [Read More]

Publications more

  • Justice Department Seeks Increased Funding for Fraud Prevention and Enforcement; Financial, Mortgage and Healthcare Fraud Remain Key Priorities in FY 2011 Budget [Read More]
  • Massachusetts Makes Energy Efficiency “First Fuel”; 3-Year Utility Plans Approved by DPU [Read More]
  • Employment Bulletin - February 5, 2010 [Read More]
  • Commercializing Stem Cell-Based Therapies: Meeting NIH and FDA Requirements [Read More]

Events more

February 10, 2010 Developing Consulting Alliances and Partnerships: Wishful Thinking or Reality? [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
February 10, 2010 The Sustainability Revolution: What Does It Mean Today to Investors, Entrepreneurs and Everyone  [Read More] MIT Stata Center, Kirsch Auditorium
Cambridge, MA
February 16, 2010 Greening of America: Bio-based Energy and Sustainability [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
February 18, 2010 Digital Home Part 1: Connected Devices - Semiconductor & Electronics Devices Forum  [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
February 23, 2010 How Successful Entrepreneurs Do More With Less [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA

Client Successes

  • Biomedical Advanced Research and Development Authority (BARDA)
    In a move that created enormous opportunities for early-stage life sciences companies, last year the U.S. Congress revitalized the federal government’s program supporting the development of medical countermeasures critical to protecting the nation against bioterrorism and pandemic threats. The resulting legislation created an agency within the Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA). BARDA will inject more than $1 billion into research, development, and procurement of vaccines, antivirals and diagnostics. BARDA enhances coordination between government and emerging companies through support of advanced research and development, the vital phase that occurs in between basic research and commercialization. On behalf of the venture capital firm, Kleiner Perkins Caulfield & Byers, Foley Hoag worked with the HHS, Congressional members, and staff to craft legislation strengthening the nation’s response to pandemic outbreaks and bioterrorism. The key financing aspect of the legislation provides much-needed funding to allow early stage companies to traverse the “valley of death” before product commercialization. The legislation authorizes the Secretary of HHS to expedite contracts and grants, and the Director of BARDA to identify areas of unmet need, spurring further innovation and investment. BARDA institutionalizes the important partnership between the federal government and the life sciences industry, critical to safety, innovation and economic vitality. [Read More]
  • HyperBranch Medical Technology, Inc.
    For our client HyperBranch Medical Technology, Inc., a leader in the field of polymeric medical sealants, we assisted with the intellectual property portfolio strategy in connection with obtaining CE Mark designation for the company’s OcuSeal product. OcuSeal is a liquid ocular bandage used to stabilize ocular wounds following surgical or non-surgical trauma. CE Marking denotes that a product complies with all requirements of European health, safety, and environmental product legislation, and is an important step in bringing products to market overseas. HyperBranch began its research in 2004 with the objective to develop strong enough polymer sealants to ultimately replace sutures that would be easy to use, and would not interfere with natural healing. The Durham, North Carolina medical device company has also, been developing advanced surgical sealants for dura (brain), pleural (lung) and hernia mesh fixation. These products are all at various stages of clinical and pre-clinical development. Read more about HyperBranch Medical Technology here. [Read More]